NPM1 and acute myeloid leukemia: The menin inhibitor JNJ-75276617 shows potent antiproliferative activity against a range of AML cell lines and patient samples harboring KMT2Ar or NPM1mut AML in vitro, with >95.5-fold selectivity over wild-type KMT2A/NPM1 AML [32].